| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities | ||||||||
Net loss | ||||||||
-61,089 | -55,744 | -42,448 | -39,773 | -37,521 | -35,317 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||||
Depreciation and amortization | ||||||||
4,739 | 4,777 | 4,695 | 4,583 | 4,514 | 4,539 | 0 | 0 | 0 |
Accretion of discount on marketable securities | ||||||||
898 | 1,457 | 1,689 | 1,790 | 1,127 | 527 | 0 | 0 | 0 |
Stock-based compensation | ||||||||
10,733 | 10,312 | 9,699 | 7,140 | 4,894 | 2,872 | 0 | 0 | 0 |
Recognition of expense (income) on derivative liability | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Reduction of the liability attributable to a research, development and commercialization agreement | ||||||||
- | - | - | - | - | - | - | - | 0 |
Accretion of debt discount | ||||||||
- | - | - | - | - | - | - | - | 0 |
Revaluation of SutroVax option liability | ||||||||
- | - | - | - | - | - | - | - | 0 |
Other | ||||||||
-101 | -193 | -112 | -489 | -375 | -337 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | ||||||||
5,741 | 3,809 | 5,088 | 3,316 | -817 | 865 | 0 | 0 | 0 |
Prepaid expenses and other assets | ||||||||
360 | 1,441 | 1,227 | 1,553 | 1,754 | 2,220 | 0 | 0 | 0 |
Accounts payable | ||||||||
- | 2,253 | 1,821 | 2,168 | 874 | 209 | 0 | 0 | 0 |
Accrued compensation | ||||||||
442 | -200 | 543 | -514 | -2,117 | 2,578 | 0 | 0 | 0 |
Other liabilities | ||||||||
-956 | 186 | -726 | 564 | 904 | 551 | 0 | 0 | 0 |
Deferred rent | ||||||||
96 | 67 | 39 | 9 | -20 | -48 | 0 | 0 | 0 |
Deferred revenue | ||||||||
-12,558 | -20,186 | -22,608 | 38,738 | 39,661 | 42,305 | 0 | 0 | 0 |
Net cash used in operating activities | ||||||||
-63,612 | -65,023 | -57,802 | 5,892 | 7,548 | 12,683 | 0 | 0 | 0 |
Investing activities | ||||||||
Purchases of marketable securities | ||||||||
80,773 | 196,226 | 191,724 | 228,833 | 200,516 | 81,463 | 0 | 0 | 0 |
Maturities of marketable securities | ||||||||
128,326 | 128,576 | 116,826 | 75,000 | 40,500 | 2,750 | 0 | 0 | 0 |
Sales of marketable securities | ||||||||
25,000 | 20,000 | 0 | 0 | 0 | - | 0 | 0 | 0 |
Purchases of equipment | ||||||||
0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 |
Net cash provided by (used in) investing activities | ||||||||
68,585 | -51,131 | -57,048 | -148,675 | -157,905 | -80,190 | 0 | 0 | 0 |
Financing activities | ||||||||
Proceeds from debt refinancing | ||||||||
0 | - | - | - | - | - | - | - | - |
Payment of deferred offering costs | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Payments of debt | ||||||||
14,500 | 5,000 | 0 | 0 | 0 | - | 0 | 0 | 0 |
Proceeds from exercise of common stock options | ||||||||
0 | - | - | 0 | 0 | - | - | 0 | 0 |
Proceeds from employee stock purchase plan | ||||||||
0 | - | - | - | - | - | - | - | - |
Net cash provided by (used in) financing activities | ||||||||
11,976 | -4,184 | 85,451 | 136,753 | 170,341 | 170,785 | 0 | 0 | 0 |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Net (decrease) increase in cash, cash equivalents and restricted cash | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Supplemental disclosure of cash flow information: | ||||||||
Cash paid for interest | ||||||||
853 | 1,049 | 1,231 | 1,292 | 1,305 | 1,275 | 0 | 0 | 0 |
Supplemental disclosure of non-cash investing and financing information: | ||||||||
Purchase of property and equipment included in accounts payable | ||||||||
462 | 270 | -394 | 314 | 263 | 205 | 0 | 0 | 0 |
Deferred initial public offering costs included in accounts payable | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Embedded interest associated with program fees | ||||||||
2,884 | 3,144 | 0 | 0 | 0 | - | 0 | 0 | 0 |
Warrants issued to lenders as part of debt discount | ||||||||
0 | - | - | - | - | - | - | - | - |
Vesting of early exercised shares | ||||||||
- | - | - | - | - | - | - | - | 0 |